NYSE · QGEN
Healthcare · Medical - Diagnostics & Research
$43.69
Up+$0.02 (+0.05%)
Updated Sep 24, 2026, 1:35 AM
SID Score
5.3/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
QGEN closed at $43.69 after 19 trading sessions, up 0.76% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $44.43 | $44.47 | $43.615 | $43.69 | 1.45M |
| Sep 21, 2026 | $44.48 | $44.82 | $43.99 | $44.78 | 1.86M |
| Sep 18, 2026 | $44.30 | $44.36 | $43.31 | $43.33 | 1.75M |
| Sep 17, 2026 | $43.79 | $44.57 | $43.65 | $44.38 | 1.91M |
| Sep 16, 2026 | $42.58 | $43.455 | $42.56 | $42.90 | 1.37M |
| Sep 15, 2026 | $42.03 | $43.09 | $42.02 | $42.48 | 1.78M |
| Sep 14, 2026 | $42.92 | $42.94 | $41.74 | $41.88 | 2.04M |
| Sep 11, 2026 | $42.58 | $42.645 | $42.02 | $42.50 | 1.11M |
| Sep 10, 2026 | $42.00 | $42.625 | $41.89 | $42.13 | 1.25M |
| Sep 9, 2026 | $42.03 | $42.7299 | $41.91 | $42.50 | 1.1M |
| Sep 8, 2026 | $42.40 | $42.74 | $42.22 | $42.38 | 1.54M |
| Sep 4, 2026 | $43.19 | $43.66 | $42.79 | $43.47 | 1.92M |
| Sep 3, 2026 | $44.41 | $44.46 | $43.16 | $43.86 | 1.52M |
| Sep 2, 2026 | $43.63 | $44.915 | $43.63 | $44.20 | 2.2M |
| Sep 1, 2026 | $44.23 | $44.32 | $43.08 | $43.39 | 2.55M |
| Aug 31, 2026 | $43.04 | $43.48 | $42.57 | $43.29 | 1.35M |
| Aug 28, 2026 | $43.62 | $43.99 | $42.99 | $43.11 | 1.38M |
| Aug 27, 2026 | $43.63 | $44.18 | $43.63 | $43.74 | 1.58M |
| Aug 26, 2026 | $43.37 | $43.865 | $43.225 | $43.36 | 1.54M |
The latest Smart Investors Daily articles mentioning QGEN.
QGEN research
Company profile and research snapshot.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Aug 10, 2026 | Citigroup | Neutral | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Barclays | Equal-Weight | — |
| Jun 23, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
VENLO, Netherlands, September 18, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET.
Yahoo · Sep 17, 2026
Qiagen (NYSE:QGEN) shares gained 4% on Thursday morning following a media report that several private equity firms are considering potential offers for the molecular testing company. German publication Manager Magazin reported that TPG and Bain Capital are among the firms weighing bids for Qiagen, although it did not identify sources for the information.
Yahoo · Sep 17, 2026
On August 27, QIAGEN N.V. (NYSE:QGEN) launched QIAsymphony Connect, a new automated platform for clinical nucleic acid extraction aimed at laboratories running liquid biopsy, oncology, and infectious disease tests. The timing is notable. On August 5, QIAGEN had already posted second-quarter results that beat its own guidance, with growth pillars like Sample technologies and QIAcuity […]
SeekingAlpha · Sep 16, 2026
Qiagen N.V. (QGEN) 2026 Global Healthcare Conference September 15, 2026 9:00 AM EDTCompany ParticipantsJonathan Pratt - CEO & Member of Management...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QGEN.
